Altimmune, Inc. (ALT)Healthcare | Biotechnology | Gaithersburg, United States | NasdaqGM
2.43 USD
-0.13
(-5.078%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 1:47 a.m. EDT
The long-term outlook remains deeply precarious due to a catastrophic multi-year price collapse of nearly 95%, which serves as a stark warning of structural deterioration despite the company's biotech pedigree. While analysts project a recovery to the mid-teens, the fundamentals tell a different story: the business is burning through cash at an alarming rate with negative operating margins exceeding 3,000% and no revenue to speak of. The balance sheet, while currently bolstered by a recent capital raise, is fragile given the massive free cash flow burn. Short-term momentum is weak, evidenced by the stock trading below its 50-day and 200-day averages, and the options market confirms this pessimism with heavy put buying establishing a defensive floor around the current price. This is a high-risk speculative vehicle where the potential for a binary event-driven rally exists, but the probability of continued distress is high. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.048543 |
| MSTL | 0.049304 |
| AutoETS | 0.049745 |
| AutoARIMA | 0.070639 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 10.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.424 |
| Excess Kurtosis | -0.93 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2017-01-19 |
| Debt to Equity Ratio | 7.596 |
| Market Cap | 472,678,016 |
| Forward P/E | -3.64 |
| Beta | 0.06 |
| Website | https://altimmune.com |
As of Oct. 10, 2026, 1:47 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside. Put open interest dominates across nearly all expirations, with massive concentration in the $3.00 strike acting as a hard floor. While there is some speculative call volume at distant strikes ($20.00 for Jan '27), the overwhelming majority of capital is deployed in out-of-the-money puts, suggesting a consensus view that the stock will struggle to recover from current lows without significant catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.39249998 |
| Address1 | 910 Clopper Road |
| Address2 | Suite 201S |
| All Time High | 137.7 |
| All Time Low | 1.51 |
| Ask | 3.92 |
| Ask Size | 2 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 4,086,580 |
| Average Daily Volume3 Month | 4,209,428 |
| Average Volume | 4,209,428 |
| Average Volume10Days | 4,086,580 |
| Beta | 0.059 |
| Bid | 2.24 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 2.438 |
| City | Gaithersburg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.43 |
| Current Ratio | 26.783 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.56 |
| Day Low | 2.43 |
| Debt To Equity | 7.596 |
| Display Name | Altimmune |
| Dividend Date | 1,536,883,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,537,800 |
| Earnings Call Timestamp Start | 1,786,537,800 |
| Earnings Timestamp | 1,786,537,800 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -98,634,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.849 |
| Enterprise To Revenue | 5,884.42 |
| Enterprise Value | 182,417,008 |
| Eps Current Year | -0.58833 |
| Eps Forward | -0.66833 |
| Eps Trailing Twelve Months | -0.76 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,484,870,400 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.0413 |
| Fifty Day Average Change | -0.6113 |
| Fifty Day Average Change Percent | -0.20099957 |
| Fifty Two Week Change Percent | -39.25 |
| Fifty Two Week High | 6.44 |
| Fifty Two Week High Change | -4.01 |
| Fifty Two Week High Change Percent | -0.6226708 |
| Fifty Two Week Low | 2.43 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 2.43 - 6.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,805,400,000 |
| Float Shares | 164,340,225 |
| Forward Eps | -0.66833 |
| Forward P E | -3.6359284 |
| Free Cashflow | -48,786,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 57 |
| Fullday Change | 0.01999998 |
| Fullday Change Percent | 0.8230445 |
| Fullday Price | 2.45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -66,693,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00434 |
| Held Percent Institutions | 0.77988 |
| Implied Shares Outstanding | 194,517,701 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,536,883,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. |
| Long Name | Altimmune, Inc. |
| Market | us_market |
| Market Cap | 472,678,016 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_4866807 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -91,760,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 620,511,466 |
| Number Of Analyst Opinions | 9 |
| Open | 2.56 |
| Operating Cashflow | -76,508,000 |
| Operating Margins | -3,184.9355 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 32.62 |
| Phone | 240 654 1450 |
| Pre Market Change | 0.01999998 |
| Pre Market Change Percent | 0.8230445 |
| Pre Market Price | 2.45 |
| Pre Market Time | 1,791,982,219 |
| Previous Close | 2.56 |
| Price Eps Current Year | -4.1303353 |
| Price Hint | 4 |
| Price To Book | 0.99671865 |
| Price To Sales Trailing12 Months | 15,247.678 |
| Profit Margins | 0.0 |
| Quick Ratio | 26.368 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -5.07812 |
| Regular Market Day High | 2.56 |
| Regular Market Day Low | 2.43 |
| Regular Market Day Range | 2.43 - 2.56 |
| Regular Market Open | 2.56 |
| Regular Market Previous Close | 2.56 |
| Regular Market Price | 2.43 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 3,707,327 |
| Return On Assets | -0.17198999 |
| Return On Equity | -0.28875 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 194,517,701 |
| Shares Percent Shares Out | 0.2369 |
| Shares Short | 46,079,911 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 49,714,773 |
| Short Name | Altimmune, Inc. |
| Short Percent Of Float | 0.23719999 |
| Short Ratio | 11.98 |
| Source Interval | 15 |
| State | MD |
| Symbol | ALT |
| Target High Price | 28.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 17.11111 |
| Target Median Price | 17.0 |
| Total Cash | 326,280,992 |
| Total Cash Per Share | 1.677 |
| Total Debt | 36,020,000 |
| Total Revenue | 31,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.76 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.39525 |
| Two Hundred Day Average Change | -0.96525 |
| Two Hundred Day Average Change Percent | -0.28429422 |
| Type Disp | Equity |
| Volume | 3,707,327 |
| Website | https://altimmune.com |
| Zip | 20,878 |